Breast

Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

(Lilly) Apr 24, 2017 - Eli Lilly and Company today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS).

read corporate press release

Growing Body Of Evidence Supports Use Of Mind-Body Therapies In Breast Cancer Treatment

(HealthCanal.com) Apr 24, 2017 - Meditation and yoga get highest grades for improving quality of life; dietary supplements get low marks for symptoms and side effects.

read article

Grail Initiates Massive Multicenter Breast Cancer Study

(MedCity News) Apr 20, 2017 - Illumina spin-out Grail announced a new multicenter clinical study on Thursday and, true to form, it’s a large-scale endeavor.

read article (free registration required)

New Technique Tests Therapies for Breast Cancer Metastasis

(Baylor) Apr 21, 2017 - A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone.

read article

Dying Cancer Patients Left To 'Face The Abyss Alone' Amid Nurse Shortages

(The Telegraph [UK]) Apr 21, 2017 - Women with incurable breast cancer are being abandoned to "face the abyss" alone because almost half of hospitals don't have specialist nurses, a new report warns.

read article

AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer

(AbbVie) Apr 19, 2017 - AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor did not meet their primary endpoints.

read corporate press release

FDA Clears Second Scalp Cooling System for Hair Loss in Patients With Breast Cancer

(Curetoday.com) Apr 19, 2017 - The Food and Drug Administration (FDA) has cleared for marketing the nation’s second cooling cap — Paxman Scalp Cooling System — to reduce hair loss in patients with breast cancer undergoing chemotherapy.

read article

Doubts Over AbbVie PARP Inhibitor After Double Trial Failure

(pharmaphorum [UK]) Apr 20, 2017 - AbbVie’s hopes of getting a so-called PARP inhibitor cancer drug to market are fading after its veliparib failed in two late-stage studies.

read article

FDA OKs Paxman Scalp Cooler for Chemo-Related Hair Loss

(Medscape) Apr 19, 2017 - US Food and Drug Administration (FDA) has given marketing clearance for the Paxman Scalp Cooling System for reducing hair loss in breast cancer patients undergoing chemotherapy.

read article (free registration required)

Experimental Drug Could Lead to Potent Combination In Breast and Other Cancers

(ICR [UK]) Apr 20, 2017 - An experimental drug could be used in combination with chemotherapy as a treatment for breast and other cancers, new research shows.

read article

When to Tell Daughters About a Genetic Breast Cancer Risk

(New York Times) Apr 20, 2017 - Some experts recommend telling minors about genetic risk so they have time to come to terms with it.

read article

Pathologic Complete Response to Neoadjuvant Therapy in Certain Breast Cancer Patients Predicts Low Risk for Local Metastases

(MD Anderson) Apr 19, 2017 - Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center.

read press release

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

(TheStreet) Apr 18, 2017 - FDA cancer drug chieftain Rick Pazdur allotted five hours, or half a day, to review Puma Biotechnology's breast cancer drug neratinib at an advisory committee meeting scheduled for May 24.

read article

This Tech Was Meant To Explore Space. Can It Also Solve The Mysteries Of Breast Cancer?

(STAT) Apr 18, 2017 - For decades, scientists here at NASA’s Jet Propulsion Laboratory have sent spacecraft deep into the solar system. Now, they’re exploring another mysterious terrain: the human breast.

read article

Scientists Identify New Way Of Attacking Breast Cancer

(ICR [UK]) Apr 18, 2017 - A team at The Institute of Cancer Research, London, working with a team at the Cancer Research UK Manchester Institute at The University of Manchester, discovered that a protein called lysyl oxidase, or LOX, plays an important role in driving breast cancer growth and cancer spread (metastasis).

read article

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

(Yahoo! Finance) Apr 17, 2017 - Puma Biotechnology, Inc., a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on May 24, 2017.

read article

Are Oncologists Jumping the Gun with the 21-Gene Assay?

(NCCN) Apr 13, 2017 - University of Colorado Cancer Center Study uncovers discrepant decision-making for use of 21-gene assay in women with cancer: Testing occurs in high-risk population, despite current evidence; non-concordance with NCCN Guidelines® recommendations; racial and socio-economic disparities found in testing use.

read press release

Which Patients Will Be Helped By Immune Cancer Drugs? This Test May Tell

(Forbes) Apr 12, 2017 - It's possible that tumor mutation burden (TMB) predicts if cancer―of any type―will respond to treatment with immune drugs, but this remains to be tested.

read article

Physicians' Misunderstanding of Genetic Test Results May Hamper Mastectomy Decisions for Breast Cancer Patients

(Stanford Medicine) Apr 12, 2017 - Women with breast cancer do not receive timely genetic testing or have adequate access to effective genetic counseling, which may compromise treatment decisions, according to research from Stanford and the University of Michigan.

read press release

Cancer Drug Kadcyla Approved For Use by NHS Scotland

(BBC News) Apr 10, 2017 - A breast cancer drug which is being withdrawn in England because it is too expensive is being made available on the NHS in Scotland.

read article
Next Page